Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
gptkb:skincare_product
|
| gptkbp:associated_with |
gptkb:Insurance_Company
stress hormonal changes smoking sun exposure genetic predisposition certain medications chronic inflammation viral infections dietary factors other autoimmune diseases thymoma immune system disorders |
| gptkbp:caused_by |
autoantibodies
|
| gptkbp:clinical_trial |
ongoing studies
biomarker research painful lesions treatment efficacy studies pruritus new drug evaluations erythema long-term outcome studies |
| gptkbp:complications |
secondary infections
scarring |
| gptkbp:current_use |
gptkb:pemphigus_vulgaris
|
| gptkbp:first_described_by |
1970s
|
| gptkbp:gender |
more common in females
|
| https://www.w3.org/2000/01/rdf-schema#label |
pemphigus foliaceus
|
| gptkbp:is_a_route_for |
desmoglein 1
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:premiered_on |
adulthood
|
| gptkbp:research_focus |
genetic factors
environmental triggers new therapies understanding autoimmunity |
| gptkbp:social_responsibility |
variable
biopsy direct immunofluorescence higher incidence in certain populations |
| gptkbp:symptoms |
scaling
blisters |
| gptkbp:treatment |
gptkb:mycophenolate_mofetil
gptkb:cyclophosphamide gptkb:rituximab gptkb:azathioprine corticosteroids intravenous immunoglobulin plasma exchange immunosuppressants dapsone |
| gptkbp:bfsParent |
gptkb:pemphigus_vulgaris
|
| gptkbp:bfsLayer |
5
|